| Ytd | -55.77% | |
| 1y | -62.37% |
| Open | 1.83 | Prev Close | 1.80 | Low | 1.83 | High | 1.84 | Mkt Cap | 3.52M |
| Vol | 294.00 | Avg Vol | 74.93K | EPS | -10.60 | P/E | -0.17 | Forward P/E | -0.43 |
| Beta | 1.71 | Short Ratio | 0.42 | Inst. Own | 3.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 1.55 | 200-d Avg | 3.04 | 1yr Est | 13.83 |
DWTX News
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) shares traded up 4.3% during trading on M
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”)
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in adva
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a biopharmace
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional saf
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.15) per share which met the anal
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fal
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or th
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company tha
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharm
REGENXBIO (NASDAQ: RGNX - Get Free Report) and Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report)
Dogwood Therapeutics (NASDAQ: DWTX - Get Free Report) is projected to issue its Q4 2025 results befo
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.26) per share which beat the ana
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”
Shares of Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) were up 1.7% during mid-day tra
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halne
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX" or "Company"), a company that focus
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) was the recipient of a significant increa
ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX”
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expect
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expect
Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Sy
On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), en
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and p
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and p
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.20) per share which missed the a
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology
HC Wainwright & Co. analyst Sean Lee maintains Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The comp
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
LRMR: -53% | Larimar shares are trading lower after the company reported seven patients experienced
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(1.99) per share which missed the a